Is Bristol-Myers Squibb a Buy?
Could the big pharma stock's short-term pain turn into long-term gain for patient investors?
Bristol-Myers Squibb
BMY
BMY
$49.43
-$0.18
-0.4%
BATS BZX Real Time Price as of September 13, 2019, 4:00 p.m. EDT
View Interactive BMY Charts
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis: Bristol-Myers Squibb
The Fool has written over 1000 articles on Bristol-Myers Squibb.
What Happened in the Stock Market Today
Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming a retail collaboration.
Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win
Here's who wins the most from the sale of Otezla.
3 Cancer Treatment Stocks to Buy Right Now
Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.
5 Top Cancer-Fighting Stocks to Buy Now
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
3 Cancer Treatment Stocks to Buy Right Now
These three businesses are poised to profit from the war on cancer.
Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2019.
5 Things You Need to Know From Bristol-Myers Squibb's Q2 Earnings Update
The big pharma company had good news and bad news. But the good news outweighed the bad.
How to Invest in Cancer-Fighting Stocks
Seven steps to help you invest more effectively in the war on cancer.
